Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  European Journal of Endocrinology

• Publication date

  1996-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1530/EJE.0.1350678PMID 9025712
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Metabolic modulation of the growth hormone-releasing activity of hexarelin in man.

  1995cited by this paper
• Modulation of growth hormone-releasing activity of hexarelin in man.

  1995cited by this paper
• Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6, and pyridostigmine in normal and obese subjects.

  1995cited by this paper
• Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: evidence that GHRP-6 main action is exerted at the hypothalamic level.

  1995cited by this paper
• In obesity the somatotrope response to either growth hormone-releasing hormone or arginine is inhibited by somatostatin or pirenzepine but not by glucose.

  1995cited by this paper
• Acipimox potentiates growth hormone (GH) response to GH-releasing hormone with or without pyridostigmine by lowering serum free fatty acid in normal and obese subjects.

  1995cited by this paper
• The growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects.

  1995cited by this paper
• GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats.

  1994cited by this paper
• Growth hormone-releasing activity of hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal, and oral administration in man.

  1994cited by this paper
• Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man.

  1993cited by this paper
• GH Releasing Peptides - Structure and Kinetics

  1993cited by this paper
• Repetitive GHRH Administration Fails to Increase the Response to GHRH in Obese Subjects

  1993cited by this paper
• Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: evidence for a marked somatotroph secretory capability in obesity.

  1993cited by this paper
• Arginine potentiates but does not restore the blunted growth hormone response to growth hormone-releasing hormone in obesity.

  1992cited by this paper
• Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors.

  1992cited by this paper
• Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes.

  1992cited by this paper
• On the actions of the growth hormone-releasing hexapeptide, GHRP.

  1991cited by this paper
• Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man.

  1991cited by this paper
• Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 stimulate growth hormone release through distinct receptor sites.

  1991cited by this paper
• Interaction of glucose and pyridostigmine on the secretion of growth hormone (GH) induced by GH-releasing hormone (GHRH)

  1990cited by this paper
• Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone.

  1990cited by this paper
• Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.

  1990cited by this paper
• Very-low-calorie diet-induced weight reduction reverses impaired growth hormone secretion response to growth hormone-releasing hormone, arginine, and L-dopa in obesity.

  1990cited by this paper
• Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects.

  1989cited by this paper
• Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?

  1989cited by this paper
• The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3',5'-monophosphate accumulation in rat primary pituitary cell culture.

  1989cited by this paper
• Binding of a growth hormone releasing hexapeptide to specific hypothalamic and pituitary binding sites.

  1989cited by this paper
• ADDITIVE EFFECTS OF GROWTH HORMONE RELEASING FACTOR AND INSULIN HYPOGLYCAEMIA ON GROWTH HORMONE RELEASE IN MAN

  1987cited by this paper
• Cholinergic agonist and antagonist drugs modulate the growth hormone response to growth hormone-releasing hormone in the rat: evidence for mediation by somatostatin.

  1986cited by this paper
• Parallel studies of His-DTrp-Ala-Trp-DPhe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture.

  1985cited by this paper
• The effect of glucose on growth hormone (GH)-releasing hormone-mediated GH secretion in man.

  1985cited by this paper
• Hyperinsulinemia suppresses glucose utilization in specific brain regions: in vivo studies using the euglycemic clamp in the rat.

  1985cited by this paper
• Impaired growth hormone responses to growth hormone-releasing factor in obesity. A pituitary defect reversed with weight reduction.

  1984cited by this paper
• The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats.

  1984cited by this paper
• Insulin suppresses growth hormone secretion by rat pituitary cells.

  1984cited by this paper
• ORAL GLUCOSE INHIBITS GROWTH HORMONE SECRETION INDUCED BY HUMAN PANCREATIC GROWTH HORMONE RELEASING FACTOR 1–44 IN NORMAL MAN

  1984cited by this paper
• Release of somatostatin-like immunoreactivity from incubated rat hypothalamus and cerebral cortex. Effects of glucose and glucoregulatory hormones.

  1982cited by this paper
• Endocrine function in human obesity.

  1981cited by this paper
• Excessive Insulin Response to Glucose in Obese Subjects as Measured by Immunochemical Assay

  1963cited by this paper

• Investigating the role of melanocortin system in regulating linear growth and growth hormone secretion

  2014cites this paper
• Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly

  2003cites this paper
• Neuroendocrine and metabolic determinants of the adaptation of GH/IGF-I axis to obesity.

  2002cites this paper
• The GH/IGF-I axis in obesity: influence of neuroendocrine and metabolic factors

  2000cites this paper
• Effects of Alprazolam, a Benzodiazepine, on the ACTH-, GH- and PRL-Releasing Activity of Hexarelin, a Synthetic Peptidyl GH Secretagogue (GHS), in Patients with Simple Obesity and in Patients with Cushing's Disease

  1999cites this paper
• Growth hormone in obesity

  1999cites this paper
• Neuroendocrine control of growth hormone secretion.

  1999cites this paper
• Chapter 15 – GHRP-s in Human Obesity

  1999cites this paper
• Chapter 12 – Hormonal Activities of Growth Hormone Secretagogues (GHS) across Human Lifespan

  1999cites this paper
• Growth hormone-releasing peptides and their analogs.

  1998cites this paper
• Orally active growth hormone secretagogues: state of the art and clinical perspectives.

  1998cites this paper
• The effect of body composition on hexarelin‐induced growth hormone release in normal elderly subjects

  1998cites this paper
• Age‐related growth hormone‐releasing activity of growth hormone secretagogues in humans

  1997cites this paper
• In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion.

  1997cites this paper
• Growth hormone-releasing peptides.

  1997cites this paper